<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04907253</url>
  </required_header>
  <id_info>
    <org_study_id>2021-2761</org_study_id>
    <nct_id>NCT04907253</nct_id>
  </id_info>
  <brief_title>Quercetin in Coronary Artery By-pass Surgery</brief_title>
  <acronym>Q-CABG</acronym>
  <official_title>Étude randomisée contrôlée Par Placebo de Phase II Visant à Mesurer l'Effet Anti-inflammatoire et Anti-sénescence de la quercétine Lors d'Une Chirurgie Cardiaque</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montreal Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montreal Heart Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the anti-inflammatory and anti-senescence effects of&#xD;
      quercetin during coronary artery by-pass graft surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed about the study and the potential risk, all patients giving written&#xD;
      informed consent will be randomized in a double-blind manner (participant and investigators)&#xD;
      on 1:1 ratio to receive quercetin (500 mg twice daily) or placebo (twice daily) starting 2&#xD;
      days before a coronary artery by-pass graft surgery and for the duration of their&#xD;
      hospitalization but up to 10 days (i.e. up to 7 days post-surgery). Blood (5 ml) will be&#xD;
      collected the first morning after recruitment (t-1), 24h post-surgery (t1), day 4&#xD;
      post-surgery (t2) and day of hospital discharge for blood analyses. During the surgery, if a&#xD;
      discarded segment of mammary artery is available, it will be collected for laboratory work.&#xD;
      Health status will be assessed during the follow-up visit 8 to 12 weeks post-surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo-controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Allocation of randomization numbers by the pharmacist provided as a randomization list prepared by the biostatisticians of the Montreal Heart Institute</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Quercetin-associated change in surgery-associated inflammation</measure>
    <time_frame>Baseline, 1 day and 4 days post-surgery</time_frame>
    <description>Circulating blood levels of hs-CRP (mg/L) will be measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quercetin-associated change in surgery-associated marker of senescence</measure>
    <time_frame>Baseline, 1 day and 4 days post-surgery</time_frame>
    <description>Circulating blood levels of ANGPTL2 (ng/L) will be measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quercetin-dependent change in endothelium-dependent relaxation</measure>
    <time_frame>During surgery</time_frame>
    <description>When available, a discarded segment of the mammary artery will be collected at the end of the cardiac surgery.&#xD;
One portion of the segment will be used to study the endothelium-dependent relaxation ex vivo. Segments will be mounted on a wire myograph. After an equilibration period, it will be pre-contracted with U46619 (0.1 µM): when the pre-contraction is stable, a cumulative dose-response curve to acetylcholine is built to induce an endothelium-dependent relaxation. Relaxation will be determined by two parameters, the vascular sensitivity to acetylcholine (µM) and the maximal relaxation induced by acetylcholine (% of relaxation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quercetin-dependent change in senescent endothelial cell load</measure>
    <time_frame>During surgery</time_frame>
    <description>When available, a discarded segment of the mammary artery will be collected at the end of the cardiac surgery.&#xD;
One portion of the segment will be used to isolate arterial wall cell nuclei for single nuclei mRNA sequencing. Senescence is assessed by expression levels of p21 mRNA, p16 mRNA and ANGPTL2 mRNA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quercetin-dependent change in senescent arterial wall cell load</measure>
    <time_frame>During surgery</time_frame>
    <description>When available, a discarded segment of the mammary artery will be collected at the end of the cardiac surgery.&#xD;
One portion of the segment will be stored at -80oC for bulk mRNA sequencing. Arterial wall senescence will be assessed by expression levels of p21 mRNA, p16 mRNA and ANGPTL2 mRNA.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Health status at follow-up visit.</measure>
    <time_frame>8 to 12 weeks post-surgery</time_frame>
    <description>During the follow-up visit, routine patient questioning will be performed and medical file will be reviewed for noticeable change in health status.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Quercetin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving 500 mg quercetin twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receiving placebo twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quercetin</intervention_name>
    <description>500 mg twice daily</description>
    <arm_group_label>Quercetin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  to be able to speak French or English;&#xD;
&#xD;
          -  to be able to give free and enlighten consent;&#xD;
&#xD;
          -  be hospitalized and waiting for a cardiac surgery of revascularization;&#xD;
&#xD;
          -  to have had a myocardial infarction (MI) within the past 30 days or to be in a state&#xD;
             of stable angina before the surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  to be in a stable state without MI in the last 30 days;&#xD;
&#xD;
          -  have a cardiac surgery concomitant to the cardiac surgery of revascularization;&#xD;
&#xD;
          -  have an infection in the last 30 days;&#xD;
&#xD;
          -  to have renal insufficiency (GFR less than 30);&#xD;
&#xD;
          -  to have a liver disease (AST, ALT or bilirubin ˃ 2X normal values);&#xD;
&#xD;
          -  to have a known cirrhosis;&#xD;
&#xD;
          -  to have a past history of breast cancer or other tumors estrogen-dependent;&#xD;
&#xD;
          -  to be intolerant to flavonoids, niacine or ascorbic acid;&#xD;
&#xD;
          -  take quinolone;&#xD;
&#xD;
          -  need for a quinolone during post-op;&#xD;
&#xD;
          -  not being able to give a free and enlighten consent;&#xD;
&#xD;
          -  not being able to speak French of English;&#xD;
&#xD;
          -  take quercetin as a supplement.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Carrier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Heart Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric Thorin, PhD</last_name>
    <phone>1-514-376-3330</phone>
    <phone_ext>3589</phone_ext>
    <email>eric.thorin@umontreal.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michel Carrier, MD</last_name>
    <phone>1-514-376-3330</phone>
    <email>michel.carrier@icm-mhi.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Thorin, PhD</last_name>
      <phone>1-514-376-3330</phone>
      <phone_ext>3589</phone_ext>
      <email>eric.thorin@umontreal.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Noly PE, Labbé P, Thorin-Trescases N, Fortier A, Nguyen A, Thorin E, Carrier M. Reduction of plasma angiopoietin-like 2 after cardiac surgery is related to tissue inflammation and senescence status of patients. J Thorac Cardiovasc Surg. 2019 Sep;158(3):792-802.e5. doi: 10.1016/j.jtcvs.2018.12.047. Epub 2019 Jan 8.</citation>
    <PMID>30745045</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inflammation</keyword>
  <keyword>Endothelium</keyword>
  <keyword>Senescence</keyword>
  <keyword>Vascular reactivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quercetin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

